Connect with us

Entrepreneur

Can a digital coach truly support menopause in the workplace?

Published

on

By Gail MacLeitch, psychotherapist and VP of AI communications provider QuickBlox, and Leslie Taylor, co-founder of Half the Sky, the team behind BestYet—a digital platform which helps women take control of their menopausal journey.

Despite spending more than a third of their lives in menopause, most women face this transition with little support, personally or professionally. Instead, women tend to navigate menopause alone, often unclear on the full extent of what to expect, or when to expect it, until it arrives.

In 2024, nearly one-third of women said menopause impacted their job performance. Women reported reducing their work hours, turning down promotions, and quitting as outcomes of their symptoms. These numbers represent daily struggles playing out in the workplace.

Companies in 18 U.S. states, including Washington, California, Colorado, and New York, already offer their employees mandatory paid sick leave, but women have reported being penalized for using this time to cope with the side effects of menopause. Even in states with progressive leave policies, cultural stigma and managerial bias undermine their intended protection.

A UK study found that only a quarter of women taking sick leave felt able to tell their managers the real reason for their absence. While many wanted to protect their privacy, 34% said they were embarrassed, and another 32% said an unsupportive manager prevented them from speaking up.

Many of the symptoms women struggle with, such as self-doubt, low patience, heightened stress, and difficulty sleeping, can be helped with the right support.

Understanding Personal Symptoms

According to a survey of over 2,000 menopausal women in the UK, 84% experienced trouble sleeping, 73% experienced ‘brain fog’, and 69% experienced difficulties with anxiety or depression during menopause. However, the scale at which symptoms impact women varies and evolves over time.

What symptoms are your employees experiencing? How are these side effects influenced by controllable aspects of their lives, such as diet, exercise, and medication?

Companies can empower women with the tools to easily track and monitor their menopausal symptoms with secure and private daily logs. These tools help surface patterns in fatigue, mood, and concentration, correlated with sleep, food, and stress. Apps such as Health and Her and MENO already demonstrate similar solutions, providing individualized recommendations, such as meal guidance, mindfulness, and wellness nudges, based on symptom tracking and progress.

Gaining Confidential Guidance

Many women-centric midlife and menopause platforms are becoming available. Women who have used these report feeling more knowledgeable, confident, and in control of their menopause journey. The apps encourage self-reflection and build confidence around menopause discussions.

However, while menopause-at-work policies are becoming more common, conversations about accommodations remain deeply personal. Employers and managers should create safe pathways for private check-ins. Digital tools can help prep both parties with the right frameworks.

For example, a well-designed menopause support app might include pre-meeting reminders to ensure respectful, informed dialogue. Building guidance on how to handle disclosures and requests into the manager’s app user journey helps guarantee they see the right information when they need it. As menopause policies increasingly become mandatory, automated summaries that record what was discussed, what was agreed, and how confidentiality will be upheld provide a transparent data trail to protect both parties.

Companies can go a step further by using secure, no-code chatbot builders to provide 24/7 support. These tools, trained on medical research, HR policy, and expert guidance, can offer calm, evidence-based responses. When used responsibly, AI-enhanced chat tools become a supplemental layer of support and enable users to navigate to other pertinent workplace benefits and providers.

Building a Community

A problem shared is a problem halved, and this is especially true for menopause.

Women benefit from sharing what works and what doesn’t, from diet to hormone replacement therapy (HRT) to mindset. But often, just feeling understood can be transformative, especially in an isolating workplace context.

Features companies must consider for their female employees include:

  • Community support: A private, judgment-free space to connect with other women navigating menopause, share stories, and exchange tips that actually work. Women can gain emotional and practical support by engaging in forum discussions.
  • Daily prompts: Affirmations, meal suggestions, lifestyle tips, and wellness nudges that spark engagement.
  • HR integration: Integrated menopause apps can give HR anonymized data on employee well-being and resource use. No or low-code tools can be embedded directly with no technical expertise, meaning HR teams can launch a wellness resource tailored to their workforce with minimal effort.

This support should extend across the organization. Menopause literacy for male employees, team leaders, and executives reduces stigma. Including resources and workshops directed at the company as a whole will help lead to a more empathetic workforce.

So, can a digital coach truly support menopause in the workplace? Yes, when it’s designed with empathy, grounded in science, and built to empower. The right digital tools don’t just track symptoms, they help women advocate for themselves, stay engaged, and thrive in their roles. The companies that design for midlife now won’t just support women. They’ll set the standard for what inclusive, intelligent, and future-ready health tech in the workplace can be.

Entrepreneur

Sun Pharma to acquire Organon in US$11bn deal

Published

on

Indian pharmaceutical giant Sun Pharma has agreed to buy Organon for US$11.75bn in a deal aimed at expanding its women’s health and biosimilars business.

Organon, which was spun out of Merck in 2021, has built a portfolio of more than 70 women’s health and general medicines products, including biosimilars, sold in the US and about 140 other countries.

The acquisition would give Sun Pharma a broader presence in biosimilars, which are medicines designed to be highly similar to existing biological drugs, and strengthen its position in women’s health.

Dilip Shanghvi, executive chairman of Sun Pharma, said: “Organon’s portfolio, capabilities, and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.”

The companies said the combined business would generate annual revenue of US$12.4bn, operate across 150 countries and rank among the top three companies globally in women’s health.

They also said it would become the seventh largest biosimilar player.

Sun Pharma said the deal would help grow its innovative medicines business and expand its biosimilars offering.

It added that the combined company would have 18 large markets each generating more than US$100m in revenue.

Organon’s largest markets include the US, Brazil, Canada, China and countries in the European Union. The company also has six manufacturing facilities across the EU and emerging markets.

The deal follows market speculation that began on 10 April, when Indian media reported that Sun Pharma had submitted an all-cash offer for Organon.

A later report said the offer had been revised to US$13bn. Sun Pharma shares rose about 7 per cent on India’s National Stock Exchange after the announcement.

Sun Pharma said it would acquire all of Organon’s issued and outstanding shares in cash, using a combination of available cash and committed bank financing. It also estimated synergies of about US$350m within two to four years of completion.

The company said the acquisition would strengthen its cash generation, with EBITDA and cash flow set to nearly double, supporting efforts to reduce the net debt to EBITDA ratio of 2.3 times resulting from the deal. EBITDA is a measure of operating performance before certain costs are deducted.

Organon reported revenue of US$6.2bn last year and adjusted EBITDA of US$1.9bn. It also reported debt of US$8.64bn, down from US$9.5bn when it separated from Merck, and a cash balance of US$574m.

In November, Organon announced plans to sell its JADA System, designed to control and treat abnormal postpartum uterine bleeding or haemorrhage, to Laborie Medical Technologies for up to US$465m. Net proceeds from the sale will contribute to Organon’s cash balance as of 31 March 2026.

Organon will merge with a subsidiary of Sun Pharma, with Organon surviving the merger. The boards of both companies have approved the transaction.

Carrie Cox, executive chair of Organon, said: “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders.”

The transaction is expected to close in early 2027, subject to regulatory approvals and Organon stockholder approval.

Continue Reading

News

Women’s digital health market set to reach US$5.28 billion in 2026 – report

Published

on

The women’s digital health market is set to reach US$5.28bn in 2026, up from US$4.36bn in 2025, according to a new report.

That would represent annual growth of 20.9 per cent, driven by factors including greater smartphone use among women, wider uptake of telehealth and a stronger focus on preventive care.

The report said the market could reach US$11.47bn by 2030, with projected annual growth of 21.4 per cent over the forecast period.

It also pointed to rising awareness of gender-specific health needs, expansion among digital health start-ups, growing demand for personalised healthcare, investment in femtech innovation and the spread of AI-enabled diagnostics.

Wearables linked to health apps and wider use of remote monitoring tools are also expected to play a larger role, as companies focus on more preventive and joined-up care.

Smartphone use was highlighted as a major driver because mobile apps are increasingly being used for women’s health services, from menstrual cycle tracking to pregnancy support.

The report cited Eurostat data showing that in 2023, 89 per cent of EU residents aged 16 to 74 in urban areas accessed the internet via smartphones.

The report also said companies in the sector are developing new technology aimed at improving access to more personalised healthcare.

One example it gave was a 2024 collaboration between Algorand and the Self-Employed Women’s Association to launch a digital health passport for women in India’s informal economy using blockchain technology.

Recent mergers and acquisitions were also noted. In March 2023, Maven Clinic acquired Naytal to expand its services in the UK and Europe.

North America was identified as the largest market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Companies named as key players included Flo Health Inc, Natural Cycles, Elvie, Bellabeat, Clue by Biowink, MobileODT Ltd., Glow, Veera Health, Biowink GmbH, Ava AG, Hims & Hers Health, Inc., The Women’s Wellness Centre, Elara Health, myGynaeDoc, Maven Clinic, Kindbody, Allara Health, Tia and Hera Med Ltd.

Continue Reading

Entrepreneur

Future Fertility raises Series A financing to scale AI tools redefining fertility care worldwide

Published

on

Future Fertility Inc. has announced the closing of a US$4.1 million Series A financing round.

The round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany) and Whitecap Venture Partners, with participation from new investors Sandpiper Ventures, Gaingels, and Jolt VC.

The financing will accelerate Future Fertility’s commercial expansion into Asia-Pacific and support its entry into the United States, including planned FDA 510(k) clearance for additional products as part of a broader U.S. market entry strategy.

Proceeds will also advance the development of a broader AI platform, from egg assessment through to embryo transfer, designed to support clinicians, embryologists, and patients across the full IVF journey.

M Ventures and Whitecap have supported Future Fertility’s mission to translate AI innovation into meaningful clinical outcomes since the company’s earliest stages.

Oliver Hardick, investment director, M Ventures, said: “Future Fertility is addressing a critical unmet need in reproductive medicine with a differentiated AI platform grounded in clinical data and real-world workflow integration.

“We are excited to continue supporting the company and team because we believe its technology has the potential to improve decision-making for clinicians, bring greater clarity to patients, and help advance a more personalised standard of care in fertility treatment.”

Future Fertility’s AI platform addresses a long-standing gap in fertility care: historically, there has been no objective, clinically validated method for assessing egg quality (Gardner et al., 2025), despite it being one of the most important drivers of reproductive success.

The company’s suite of deep learning tools includes VIOLET™, MAGENTA™, and ROSE™, purpose-built for egg freezing, IVF, and egg donation respectively.

The tools are based on AI models trained and validated on more than 650,000 oocyte images and are deployed in over 300 clinics across 35 countries.

Rhiannon Davies, founding and managing partner, Sandpiper Ventures, said:  “The best outcomes in fertility care globally come from better data and smarter tools. Future Fertility understands that, and they’ve built a platform that delivers on it.

“Sandpiper is proud to back a team turning rigorous science into real results for patients and clinicians alike.”

Partnerships with the world’s leading fertility networks – including IVI RMA and Eugin Group across Latin America and Europe, FertGroup Medicina Reproductiva in Brazil, and most recently announced Kato Ladies Clinic in Japan –  reflect growing demand for objective, AI-powered oocyte assessment in fertility care. In the United States, ROSE™ is newly available under an FDA 513(g) determination.

Research shows that approximately 50 per cent of IVF patients do not understand their likelihood of success, and many discontinue treatment prematurely, even though cumulative success rates improve significantly with multiple cycles (McMahon et al., 2024).

By delivering earlier clarity on egg quality, Future Fertility’s tools support more informed conversations between clinicians and patients, helping set realistic expectations and guide decisions about next steps.

Future Fertility’s growing evidence base spans seven peer-reviewed publications in Human Reproduction, Reproductive BioMedicine Online, Fertility & Sterility, and Nature’s Scientific Reports, and more than 70 scientific abstracts accepted and presented with partner clinics at conferences worldwide.

Christine Prada, CEO, Future Fertility, said: “Fertility treatment is one of the most emotionally and physically demanding experiences a person can go through.

“Every patient deserves objective data, not just a best guess, to support better decisions at critical moments in their care.

“This funding means we can bring that clarity to more patients, in more countries, at a moment when it matters most.”

Find out more about Future Fertility at futurefertility.com

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.